Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
IBJ-Iranian Biomedical Journal. 2017; 21 (2): 114-119
in English | IMEMR | ID: emr-186946

ABSTRACT

Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-beta are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-beta, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats


Methods: Adult male Wistar rats [n=48] were randomly divided into six groups: control, formalin+saline, ghrelin [40, 80, and 160 microg/kg], and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar [i.pl.] injection of 50 microl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-beta levels were assessed by ELISA method


Results: The findings of the present study showed that ghrelin with high doses [80 and 160 microg/kg] significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-beta1 showed a significant elevation with ghrelin at dose of 160 microg/kg


Conclusion: Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines

SELECTION OF CITATIONS
SEARCH DETAIL